Mission
ICER's mission is to lead innovation in comparative effectiveness research through methods that integrate considerations of clinical benefit and economic value. Through a unique collaboration with patients, clinicians, manufacturers, insurers and other healthcare stakeholders, ICER develops tools to support patient decisions and medical policy that share the goal of achieving maximum value for every healthcare dollar.
| Brachytherapy and Proton Beam Therapy for Clinically Localized, Low-Risk Prostate Cancer: Final Appraisal |
|
ICER completed a comprehensive comparative effectiveness appraisal of Brachytherapy and Proton Beam Therapy for Clinically Localized, Low-Risk Prostate Cancer. |
Ongoing Appraisals
Recent News Releases
- New Members of the New England Comparative Effectiveness Public Advisory Council (CEPAC) Named for 2013
- Next Public Meeting of CEPAC to Address Community Health Worker Programs
- New Report and Action Guide on Obstructive Sleep Apnea from New England CEPAC Will Help Patients, Clinicians, and Insurers Improve Care for Adults